FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307805366> ?p ?o ?g. }

• W4307805366 endingPage "A374" @default.
• W4307805366 startingPage "A374" @default.
• W4307805366 abstract "Abstract Type 2 diabetes mellitus (T2DM) is a leading cause of morbidity and mortality in people of all ages worldwide. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) offer an innovative and unique advancement in treatment for T2DM by not only benefiting blood glucose control but also potentially impacting other diabetes-related complications. However, clinical response to GLP-1 RA is not seen in all patient populations. Our goal was to determine the response rate of GLP-1 RA add-on therapy. We performed a retrospective study of veterans with T2DM initiated on any GLP-1 RA from January 1, 2015, to December 31, 2019, for a duration of at least 6 months to assess the response in terms of hemoglobin A1c (A1c), weight, and total daily insulin dose. Baseline characteristics of 332 patients were reviewed to evaluate response rate. Treatment response thresholds included an A1c reduction of at least 0.5%, weight loss of ≥ 3% of pretreatment body weight, and a ≥ 10% reduction in total daily insulin dose (TDD). We then classified veterans into those without a response, or with 1, 2, or all 3 responses based on data 6-12 months after initiating treatment. We considered it a complete response if all 3 categories were fulfilled. Semaglutide (n=141): 10.64% showed a response to A1c alone, 3.55% had weight reduction alone, and 2.84% had insulin reduction alone. 7.09% showed A1c and weight response, 24.82% had A1c and insulin response, and 13.48% had weight and insulin response. A complete response was seen in 33.33% of veterans. Liraglutide (n=131): 18.32% showed a response to A1c alone, 4.58% had weight reduction alone, and 11.45% had insulin reduction alone. 6.11% showed A1c and weight response, 19.08% had A1c and insulin response, and 8.40% had weight and insulin response. A complete response was seen in 25.19% of veterans. Dulaglutide (n=57): 22.81% showed a response to A1c alone, 3.51% had weight reduction alone, and 12.28% had insulin reduction alone. 8.77% showed A1c and weight response, 26.32% had A1c and insulin response, and 1.75% had weight and insulin response. A complete response was seen in 15.79% of veterans. In conclusion, semaglutide's most common response, in 33.33% of patients, was having a complete response, followed by a reduction in A1c and insulin reduction for 24.82% of patients, and then weight and insulin reduction for 13.48% of patients. Liraglutide's most common response, in 25.19% of patients, was having a complete response, followed by a reduction in A1c and insulin dose for 19.08% of patients, and then reduction in A1c alone for 18.32% of patients. Unlike the others, dulaglutide's most common response was not a complete response, but rather A1c and insulin reduction, for 26.32% patients. Dulaglutide also had 22.81% of patients respond with A1c alone. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m." @default.
• W4307805366 created "2022-11-06" @default.
• W4307805366 creator A5015384186 @default.
• W4307805366 creator A5042398172 @default.
• W4307805366 creator A5052935754 @default.
• W4307805366 creator A5059587904 @default.
• W4307805366 creator A5077027153 @default.
• W4307805366 date "2022-11-01" @default.
• W4307805366 modified "2023-10-18" @default.
• W4307805366 title "PSUN188 Evaluating Response to GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Managed at a Veterans Affairs Hospital" @default.
• W4307805366 doi "https://doi.org/10.1210/jendso/bvac150.778" @default.
• W4307805366 hasPublicationYear "2022" @default.
• W4307805366 type Work @default.
• W4307805366 citedByCount "0" @default.
• W4307805366 crossrefType "journal-article" @default.
• W4307805366 hasAuthorship W4307805366A5015384186 @default.
• W4307805366 hasAuthorship W4307805366A5042398172 @default.
• W4307805366 hasAuthorship W4307805366A5052935754 @default.
• W4307805366 hasAuthorship W4307805366A5059587904 @default.
• W4307805366 hasAuthorship W4307805366A5077027153 @default.
• W4307805366 hasBestOaLocation W43078053661 @default.
• W4307805366 hasConcept C126322002 @default.
• W4307805366 hasConcept C134018914 @default.
• W4307805366 hasConcept C2777180221 @default.
• W4307805366 hasConcept C2778917026 @default.
• W4307805366 hasConcept C2779306644 @default.
• W4307805366 hasConcept C2781308992 @default.
• W4307805366 hasConcept C2909862629 @default.
• W4307805366 hasConcept C2910068830 @default.
• W4307805366 hasConcept C3017594758 @default.
• W4307805366 hasConcept C3020574416 @default.
• W4307805366 hasConcept C511355011 @default.
• W4307805366 hasConcept C544821477 @default.
• W4307805366 hasConcept C555293320 @default.
• W4307805366 hasConcept C71924100 @default.
• W4307805366 hasConceptScore W4307805366C126322002 @default.
• W4307805366 hasConceptScore W4307805366C134018914 @default.
• W4307805366 hasConceptScore W4307805366C2777180221 @default.
• W4307805366 hasConceptScore W4307805366C2778917026 @default.
• W4307805366 hasConceptScore W4307805366C2779306644 @default.
• W4307805366 hasConceptScore W4307805366C2781308992 @default.
• W4307805366 hasConceptScore W4307805366C2909862629 @default.
• W4307805366 hasConceptScore W4307805366C2910068830 @default.
• W4307805366 hasConceptScore W4307805366C3017594758 @default.
• W4307805366 hasConceptScore W4307805366C3020574416 @default.
• W4307805366 hasConceptScore W4307805366C511355011 @default.
• W4307805366 hasConceptScore W4307805366C544821477 @default.
• W4307805366 hasConceptScore W4307805366C555293320 @default.
• W4307805366 hasConceptScore W4307805366C71924100 @default.
• W4307805366 hasIssue "Supplement_1" @default.
• W4307805366 hasLocation W43078053661 @default.
• W4307805366 hasLocation W43078053662 @default.
• W4307805366 hasOpenAccess W4307805366 @default.
• W4307805366 hasPrimaryLocation W43078053661 @default.
• W4307805366 hasRelatedWork W2001592304 @default.
• W4307805366 hasRelatedWork W2015380533 @default.
• W4307805366 hasRelatedWork W2018617549 @default.
• W4307805366 hasRelatedWork W2051808761 @default.
• W4307805366 hasRelatedWork W2063763413 @default.
• W4307805366 hasRelatedWork W2072354038 @default.
• W4307805366 hasRelatedWork W2088717006 @default.
• W4307805366 hasRelatedWork W2102847968 @default.
• W4307805366 hasRelatedWork W2141445964 @default.
• W4307805366 hasRelatedWork W4246065898 @default.
• W4307805366 hasVolume "6" @default.
• W4307805366 isParatext "false" @default.
• W4307805366 isRetracted "false" @default.
• W4307805366 workType "article" @default.